Literature DB >> 17602875

Involvement of Toll-like receptors in the immune response of nasal polyp epithelial cells.

Jiyun Wang1, Satoshi Matsukura, So Watanabe, Mitsuru Adachi, Harumi Suzaki.   

Abstract

Recognition systems employed by airway epithelial cells to respond to microbial exposure include the action of Toll-like receptors (TLRs). We investigated the presence and function of TLR2, 3, and 4 in primary cultures of human nasal polyp epithelial cells. dsRNA stimulation significantly enhanced the expression and secretion of RANTES, IP-10, IL-8, and GM-CSF. LPS also exhibited stimulatory action, but it was much weaker than dsRNA. Peptidoglycan had no significant stimulatory action on the genes. Flow cytometry showed that the nasal polyp epithelial cell mainly expressed TLR3 in an intracellular compartment, but expression of TLR2 and TLR4 was very low on both the cell surface and in the cell. The immune response of primary nasal polyp epithelial cells induced by TLR3 could not be blocked by anti-TLR3 antibody. Among the TLR ligands evaluated, dsRNA, the ligand for TLR3, mediated the strongest pro-inflammatory effects in primary nasal polyp epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602875     DOI: 10.1016/j.clim.2007.05.009

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  12 in total

Review 1.  Innate immunity in the respiratory epithelium.

Authors:  Dane Parker; Alice Prince
Journal:  Am J Respir Cell Mol Biol       Date:  2011-02-17       Impact factor: 6.914

2.  Chronic rhinosinusitis as a multifactorial inflammatory disorder.

Authors:  Stella Lee; Andrew P Lane
Journal:  Curr Infect Dis Rep       Date:  2011-04       Impact factor: 3.725

3.  Increased expression of chemokine receptors CCR1 and CCR3 in nasal polyps: molecular basis for recruitment of the granulocyte infiltrate.

Authors:  P Fundová; D P Funda; D Kovář; R Holý; M Navara; H Tlaskalová-Hogenová
Journal:  Folia Microbiol (Praha)       Date:  2012-10-11       Impact factor: 2.099

4.  Different activations of toll-like receptors and antimicrobial peptides in chronic rhinosinusitis with or without nasal polyposis.

Authors:  Andor Hirschberg; Maria Kiss; Edit Kadocsa; Hilda Polyanka; Kornelia Szabo; Zsolt Razga; Zsolt Bella; Laszlo Tiszlavicz; Lajos Kemeny
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-30       Impact factor: 2.503

Review 5.  Perspectives on the etiology of chronic rhinosinusitis: an immune barrier hypothesis.

Authors:  Robert C Kern; David B Conley; William Walsh; Rakesh Chandra; Atsushi Kato; Anju Tripathi-Peters; Leslie C Grammer; Robert P Schleimer
Journal:  Am J Rhinol       Date:  2008-09-10

6.  Importance of innate mucosal immunity and the promises it holds.

Authors:  Abhisek Dwivedy; Palok Aich
Journal:  Int J Gen Med       Date:  2011-04-12

7.  Engineered metal based nanoparticles and innate immunity.

Authors:  Claudia Petrarca; Emanuela Clemente; Valentina Amato; Paola Pedata; Enrico Sabbioni; Giovanni Bernardini; Ivo Iavicoli; Sara Cortese; Qiao Niu; Takemi Otsuki; Roberto Paganelli; Mario Di Gioacchino
Journal:  Clin Mol Allergy       Date:  2015-07-15

8.  Prevalence of rhinovirus and respiratory syncytial virus among patients with chronic rhinosinusitis.

Authors:  Hassan Abshirini; Manochher Makvandi; Meghdad Seyyed Ashrafi; Mojtaba Hamidifard; Nader Saki
Journal:  Jundishapur J Microbiol       Date:  2015-03-21       Impact factor: 0.747

9.  Broad-spectrum drugs against viral agents.

Authors:  Mary E Christopher; Jonathan P Wong
Journal:  Int J Mol Sci       Date:  2008-09-01       Impact factor: 6.208

10.  Expression profiling and functional analysis of Toll-like receptors in primary healthy human nasal epithelial cells shows no correlation and a refractory LPS response.

Authors:  J van Tongeren; K I L Röschmann; S M Reinartz; S Luiten; W J Fokkens; E C de Jong; C M van Drunen
Journal:  Clin Transl Allergy       Date:  2015-12-14       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.